131 related articles for article (PubMed ID: 9165756)
1. Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor.
Xiang J; Moyana T; Qi Y
J Biotechnol; 1997 Feb; 53(1):3-12. PubMed ID: 9165756
[TBL] [Abstract][Full Text] [Related]
2. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells.
Xiang J; Qi Y; Cook D; Moyana T
Hum Antibodies Hybridomas; 1996; 7(1):2-10. PubMed ID: 8886831
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
Wright P; Zheng C; Moyana T; Xiang J
Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
[TBL] [Abstract][Full Text] [Related]
4. Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein.
Shi M; Hao S; Quereshi M; Guo X; Zheng C; Xiang J
Cancer Biother Radiopharm; 2005 Jun; 20(3):260-6. PubMed ID: 15989471
[TBL] [Abstract][Full Text] [Related]
5. Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule.
Hoogenboom HR; Raus JC; Volckaert G
Biochim Biophys Acta; 1991 Jun; 1096(4):345-54. PubMed ID: 2065106
[TBL] [Abstract][Full Text] [Related]
6. A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.
Yang J; Moyana T; Xiang J
Mol Immunol; 1995 Aug; 32(12):873-81. PubMed ID: 7565814
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
Xiang J; Qi Y; Chen Y
Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
[TBL] [Abstract][Full Text] [Related]
8. Construction and expression of antibody-tumor necrosis factor fusion proteins.
Hoogenboom HR; Volckaert G; Raus JC
Mol Immunol; 1991 Sep; 28(9):1027-37. PubMed ID: 1922108
[TBL] [Abstract][Full Text] [Related]
9. A genetically engineered fusion protein M4/TNF with increased bifunctional activity refolded in the presence of protein disulfide isomerase.
Yang J; Raju R; Sharma R; Xiang J
Hum Antibodies Hybridomas; 1995; 6(4):129-36. PubMed ID: 8688495
[TBL] [Abstract][Full Text] [Related]
10. Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-tau.
Xiang J
Cancer Biother Radiopharm; 1997 Apr; 12(2):123-30. PubMed ID: 10851456
[TBL] [Abstract][Full Text] [Related]
11. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-gamma [corrected] elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Qi Y; Chen Y; Xiang J
J Interferon Cytokine Res; 1996 Oct; 16(10):771-6. PubMed ID: 8910761
[TBL] [Abstract][Full Text] [Related]
12. A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells.
Qi Y; Xiang J
Hum Antibodies Hybridomas; 1995; 6(4):161-6. PubMed ID: 8688499
[TBL] [Abstract][Full Text] [Related]
13. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau.
Qi Y; Moyana T; Chen Y; Xiang J
Hum Antibodies Hybridomas; 1996; 7(1):21-6. PubMed ID: 8886833
[TBL] [Abstract][Full Text] [Related]
14. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.
Better M; Bernhard SL; Lei SP; Fishwild DM; Lane JA; Carroll SF; Horwitz AH
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):457-61. PubMed ID: 7678457
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
Khawli LA; Alauddin MM; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
[TBL] [Abstract][Full Text] [Related]
16. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
Xiong DS; Zheng MJ; Liu YX; Xu YF; Wang JH; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):673-8. PubMed ID: 15973988
[TBL] [Abstract][Full Text] [Related]
17. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
20. Differences in antigen-binding affinity caused by a single amino acid substitution in the variable region of the heavy chain.
Xiang J; Chen Z; Delbaere LT; Liu E
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():239-47. PubMed ID: 8225393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
